MapLight Therapeutics (MPLT) Interest & Investment Income (2024 - 2026)
MapLight Therapeutics (MPLT) posted Interest & Investment Income of $2.5 million for Q4 2025, up 59.46% sequentially from $1.5 million in Q3 2025, and up 174.75% YoY from $899000.0 in Q4 2024.
Analysis
MapLight Therapeutics (MPLT) Interest & Investment Income (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Interest & Investment Income for 2 years, with the latest figure at $2.5 million in Q4 2025.
- Quarterly Interest & Investment Income rose 174.75% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (changed N/A YoY) and the FY2025 annual result came in at $5.5 million, up 22.51% from the prior year.
- Interest & Investment Income advanced to $2.5 million in Q4 2025 per MPLT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $2.5 million in Q4 2025 and troughed at $899000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | MapLight Therapeutics | 629.45 Mn | 629.45 Mn | - | 2.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 688,000.00 |
| Dec 31, 2024 | 899,000.00 |
| Sep 30, 2024 | 1.08 Mn |